CAMERA2 – combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial

Discussion Key potential advantages of adding anti-staphylococcal β-lactams to standard therapy for MRSA bacteraemia include their safety profile, low cost, and wide availability. Trial registration ClinicalTrials.gov Identifier: NCT02365493. Registered 24 February 2015.

http://link.springer.com/10.1186/s13063-016-1295-3

Source: Trials - March 30, 2016 Category: Research Source Type: clinical trials